Quinoline compound for combined treatment on gastric carcinoma

A compound, gastric cancer technology, applied in the field of pharmaceutical preparations and medicine, can solve problems such as lack of therapeutic drugs

Pending Publication Date: 2020-12-08
CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Based on the strong side effects of current chemotherapy and the lack of more

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinoline compound for combined treatment on gastric carcinoma
  • Quinoline compound for combined treatment on gastric carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0172] Patients with pathologically confirmed advanced gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma, Siewert type II, type III) are given anlotinib, cisplatin and S-1 in combination, and the specific dosage regimen is as follows:

[0173] Anlotinib Hydrochloride Capsules: Before breakfast, take Anlotinib Hydrochloride Capsules on an empty stomach, once a day, 12mg each time (1 capsule). Continuous oral administration for 2 weeks, stop for 1 week, that is, 3 weeks (21 days) is a treatment cycle. If there is a missed dose, it is confirmed that the time from the next dose is less than 12 hours, and no supplementary dose will be given.

[0174] Cisplatin injection: 60~80mg / m 2 Intravenous infusion, administration on d1, 3 weeks (21 days) as a treatment cycle;

[0175] S-1 capsule: 40-60mg po bid, d1-14, 3 weeks (21 days) as a treatment cycle.

[0176] Observation efficacy indicators: objective response rate (ORR=CR+PR), progression-free survival (P...

Embodiment 2

[0179] For patients with unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (including signet ring cell carcinoma, mucinous adenocarcinoma, hepatoid adenocarcinoma) confirmed by histopathological and / or cytological examination, the combination drug Rotinib and toripalimab, the specific dosage regimen is as follows:

[0180] Anlotinib hydrochloride capsules, orally, 1 time / day, 12mg / time, medication from the 1st day to the 14th day of each cycle, every 3 weeks is a treatment cycle; toripalimab, 3mg / kg, intravenous Infusion for 1h±5min, once every 2 weeks (administration on the 1st and 15th day of each cycle), every 4 weeks is a treatment cycle, until the treatment termination criteria are met. Efficacy evaluation was performed according to RECIST1.1 standard every 8 weeks.

[0181] Observe the curative effect index:

[0182] Objective response rate (ORR=PR+CR), progression-free survival (PFS), overall survival (OS), disease control rate (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The application belongs to the technical field of medicines, provides a quinoline compound for combined treatment on the gastric carcinoma and particularly provides use of combination of a compound Ior pharmaceutically acceptable salts thereof and a second therapeutic agent in preparation of drugs for treating the gastric carcinoma and a combined pharmaceutical composition for treating the gastric carcinoma. The combined pharmaceutical composition comprises: (i) the compound I or pharmaceutically acceptable salts thereof; and (ii) at least one second therapeutic agent, wherein a chemical nameof the compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinol-7-yl]oxy]methyl]cyclopropylamine.

Description

technical field [0001] The invention belongs to the field of medicine, and the invention belongs to the technical field of pharmaceutical preparations, specifically quinoline compounds or pharmaceutically acceptable salts thereof for combined treatment of gastric cancer. Background technique [0002] Gastric cancer (gastric carcinoma) is a malignant tumor originating from the mucosal epithelium on the surface of the stomach wall, and the most common sites are the pyloric antrum and the lesser curvature. In my country, the incidence of gastric cancer ranks first among all kinds of malignant tumors, and 352,300 people die of gastric cancer every year, ranking third in the mortality rate. According to statistics, China accounts for 40-50% of the new cases of gastric cancer in the world every year, and the incidence rate is much higher than that in Europe, America and other countries. There are obvious regional differences in the incidence of gastric cancer in my country, and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/4709A61P35/00A61P35/04
CPCA61K45/06A61K31/4709A61P35/00A61P35/04
Inventor 徐萍王诚倩
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products